Dynamic Industry Veteran Led Multi-Billion Dollar Therapeutic Neurotoxin Portfolio
NEWPORT BEACH, Calif., May 13, 2019 /PRNewswire/ — ALPHAEON Corporation announced today that its Board of Directors has named Marc Forth as President and Chief Executive Officer of its newly established, wholly-owned subsidiary, AEON Biopharma, Inc. AEON Biopharma was established to independently pursue the rapidly growing, multi-billion-dollar, therapeutic toxin market. Therapeutic related applications represent greater than 60% of global neurotoxin segment revenues. Mr. Forth joins AEON Biopharma from Allergan, where he was Senior Vice President of Neurosciences, Urology and Medical Dermatology. Mr. Forth led, among other brands, BOTOX® Therapeutic, an organization with annual revenues of approximately $2 Billion.
Mr. Forth has over twenty-five years of commercial and executive experience building and launching multiple market leading franchises. Mr. Forth previously also led marketing for BOTOX® Cosmetic and held various sales and marketing roles of increasing responsibility at TAP Pharmaceuticals.
“ALPHAEON’s Board of Directors is pleased to appoint Marc as President and Chief Executive Officer of AEON Biopharma,” said Simone Blank, Chairperson of ALPHAEON. She continued, “Marc’s joining AEON Biopharma represents a major milestone for the Company, as we move towards filing an Investigative New Drug Application (“IND”) for the first therapeutic indication of our 900 kDa purified botulinum toxin type A complex. Marc is one of the most experienced executives in the field of therapeutic neurotoxins, having led BOTOX® Therapeutic, the largest therapeutic neurotoxin in the world. We believe his joining further validates the promise of our botulinum toxin type A complex. We welcome Marc’s vision and passion.”
Marc Forth, President and Chief Executive Officer of AEON Biopharma, said, “I am excited to join the Company at a time when the therapeutic toxin market is already large and rapidly growing, yet also presents an expansion opportunity into several untapped new indications. I believe AEON Biopharma, with its focus on therapeutic indications only, is optimally positioned to become one of the leading players in the world of therapeutic neurotoxins. I look forward to working with the Company’s Board in assembling a best in class leadership team to help further this incredible business opportunity.”
Prior to Mr. Forth’s sixteen years at Allergan, he spent seven years at TAP Pharmaceuticals and two years in Marketing, Advertising and Public Relations at WSW Associates. He holds a Bachelor of Science degree from California State University, Fresno, CA and a Graduate Marketing Certification from Southern Methodist University, Dallas, TX.
About AEON Biopharma, Inc.
AEON Biopharma is a biopharma company dedicated to bringing advanced therapeutic procedures and treatments to physicians. AEON Biopharma is focused on developing an injectable 900 kDa purified botulinum toxin type A complex for therapeutic indications.
About ALPHAEON Corporation
ALPHAEON Corporation is a healthcare company partnered with board-certified physician specialists focusing on developing highly innovative technologies and services across multiple healthcare segments.
A Transformation of the Healthcare Experience
Empowering patients, enabling specialists, and driving innovation in the health and wellness industry.